Colossal Biosciences announced on November 4, 2025, that it has acquired Viagen, the company responsible for more commercial animal clones than any other firm in the world. The deal gives Colossal direct control of cloning, cryopreservation, and cell-banking infrastructure it says is the final operational piece needed to produce woolly mammoth calves within roughly two years. The acquisition sharpens a question conservation scientists have raised for nearly a decade: whether private capital flowing into de-extinction projects will strengthen or weaken efforts to protect species that are still alive.
How the Viagen deal changes Colossal’s mammoth timeline
Colossal has spent years editing Asian elephant DNA to express woolly mammoth traits such as cold tolerance and dense hair. The missing link was not the gene editing itself but the reproductive infrastructure to move from engineered cells to a live birth. In its own announcement, Colossal describes Viagen as a dominant cloning provider, with established protocols for somatic cell nuclear transfer, embryo culture, and surrogate pregnancies across multiple livestock species.
By absorbing Viagen rather than building cloning capacity from scratch, Colossal inherits a functioning lab pipeline, trained personnel, and an existing client base that has already demonstrated repeatability in large-mammal reproduction. That shortcut could compress the technical timeline by a year or more, because the alternative would have required Colossal to validate each step of the cloning process independently. The company now frames the birth of a mammoth-like calf as a near-term engineering milestone rather than a distant research goal, emphasizing operational execution over speculative biology.
The practical challenge, though, is that cloning elephants is not the same as cloning cattle or horses. No laboratory has publicly reported a successful elephant pregnancy from cloned embryos. Viagen’s expertise applies to domesticated species with well-characterized reproductive biology, relatively short gestations, and extensive historical data on assisted reproduction. Elephants have the longest gestation period of any land mammal and notoriously complex reproductive cycles, with long intervals between estrus and heightened sensitivity to stress and captivity.
Colossal has not released data showing that its edited elephant cell lines are ready for nuclear transfer, and no regulatory filings related to elephantid pregnancies have surfaced from the acquired Viagen labs. Until those details are public, the two-year mammoth-calf timeline rests on extrapolating from livestock performance to a species that has never been cloned, using embryos derived from heavily edited genomes. Even supporters of the project acknowledge that unexpected developmental problems could emerge once pregnancies are attempted at scale.
Conservation scientists flag the cost of chasing extinct species
For conservation biologists, the Viagen deal is less about technical feasibility than about priorities. Peer-reviewed research in Nature Ecology and Evolution examined the opportunity costs of de-extinction and concluded that redirecting scarce budgets to resurrect lost species could lead to net biodiversity loss. The study modeled funding scenarios in which governments and private donors shifted support away from threatened but still-living species and toward high-profile resurrection projects. In the modeled outcomes, fewer species survived overall because de-extinction programs were expensive and slow, while conventional conservation could protect more species per dollar.
That tension has only grown since the paper appeared. Private investment in de-extinction startups has increased, with Colossal alone raising large sums of venture capital and positioning itself as a platform for reviving multiple extinct or near-extinct species. Conservation organizations working on in-situ mammal protection, by contrast, continue to compete for a relatively fixed pool of philanthropic and government grants, often earmarked for incremental habitat work rather than moonshot science.
The Viagen acquisition adds a new dimension to that landscape. Colossal is now not just a gene-editing company but an operator of commercial cloning services, with a business model that can include pet and livestock cloning alongside experimental de-extinction work. In theory, revenue from dog, cat, or elite-bull clones could subsidize the mammoth program, reducing its reliance on traditional conservation funding and insulating it from the zero-sum dynamic that worries ecologists.
If that revenue model succeeds, Colossal could argue that it is expanding the total pool of money available for biodiversity-related science, rather than cannibalizing existing budgets. If it fails, however, the risk is that the mammoth project will continue to absorb donor and investor attention out of proportion to its direct conservation benefits. For field biologists trying to keep elephants, rhinos, or lesser-known mammals from slipping into extinction, the concern is not that Colossal is malicious, but that splashy de-extinction narratives overshadow the unglamorous work of law enforcement, community engagement, and land management.
No major conservation-funding body has publicly stated that Colossal’s budget has already displaced grants for living species. Yet the structural incentive is clear: a woolly mammoth calf would generate global media coverage and investor enthusiasm on a scale that a successful anti-poaching program or habitat corridor rarely achieves. Philanthropists and policymakers, faced with finite time and money, may gravitate toward projects that promise historic firsts and cinematic imagery, even if the expected biodiversity payoff is smaller.
Open questions before any mammoth calf is born
Several technical and ethical gaps remain between the Viagen acquisition and a live mammoth-like birth. First, Colossal has not published success-rate data for nuclear transfer using its edited elephant cells. Cloning efficiency in livestock is already low, often below five percent of transferred embryos resulting in live births, and many of those births involve health complications. Whether those rates would be even lower in elephants, given their reproductive complexity and the added burden of extensive genome editing, is unknown.
Second, the regulatory path is unclear. No U.S. or international framework specifically governs the creation of a hybrid animal that blends the genome of an extinct species with that of a living endangered one. Asian elephants are listed under the Endangered Species Act and the Convention on International Trade in Endangered Species, which triggers layers of permitting for any activity involving their tissues or movement across borders. Any project involving elephant surrogates, transport of embryos, or eventual public display of mammoth-like calves will need to navigate animal welfare review, biosafety oversight, and potential trade restrictions.
Regulators will also have to decide how to classify mammoth-like animals in law. If they are treated as Asian elephants for the purposes of protection, strict rules on ownership, breeding, and transport could apply. If they are considered a novel domestic species, looser standards might govern their use in research, tourism, or commercial attractions. Neither outcome has been fully mapped, and agencies have not yet issued guidance tailored to de-extinction efforts.
Third, the ecological rationale for mammoth de-extinction remains largely hypothetical. Proponents argue that reintroducing large herbivores to Arctic and sub-Arctic landscapes could compact winter snow, expose colder ground, and encourage grassland over shrub or forest, potentially slowing permafrost thaw and carbon release. That hypothesis has been tested only in small-scale experiments with existing animals such as horses and bison, and the results are still debated. Scaling up to herds of mammoth-like creatures would require decades of monitoring, careful management of human-wildlife conflict, and coordination with Indigenous communities whose territories overlap proposed release sites.
Finally, there is the question of animal welfare. Even if cloning protocols can be adapted to elephants, the early stages are likely to involve many failed pregnancies, miscarriages, and neonatal deaths. For an endangered species already under pressure from habitat loss and poaching, using females as experimental surrogates raises ethical concerns that go beyond standard livestock cloning debates. Colossal has said it intends to prioritize welfare and minimize suffering, but the company has not yet disclosed how many pregnancies it expects to attempt or what thresholds would trigger a pause or redesign of the program.
A test case for how far de-extinction should go
The Viagen acquisition marks a turning point for de-extinction, shifting the conversation from whether mammoth-like animals are technically possible to how they should be pursued, regulated, and justified. For Colossal, owning a mature cloning business offers a faster route to its first headline-making birth and a potential revenue stream to sustain long-term research. For conservationists, it crystallizes long-standing worries about opportunity costs, ethical boundaries, and the risk that attention will drift from the species that still have a chance to recover without being resurrected.
How governments, funders, and the public respond to this moment will help determine whether de-extinction becomes a niche spectacle, a mainstream conservation tool, or something in between. Before any mammoth calf takes its first steps, the harder work may lie in deciding what kind of future for biodiversity this technology is meant to serve.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
